More importantly, it provides the basis to investigate the potential integration of anti-GH strategies, such as pegvisomant; a short peptide that inhibits the GH/GHR signaling and is the only drug approved by FDA to treat acromegaly [14], into systemic therapy approaches in HCC. The gene discussed is GH1; the disease is hepatocellular carcinoma.